Hummingbird Biosciences could one day feather its nest with up to $290 million if its decision to license a phase 2-ready ...

Cosmo Pharmaceuticals aims to make the colonoscopy a little more up close and personal, for providers anyway, by connecting ...

While the IPO landscape remains icy, Minovia Therapeutics is skating into the market using a special purpose acquisition ...

The company’s medtech wing has launched the Polyphonic AI Fund for Surgery, and will be taking proposals from academic and ...

Bayer-owned BlueRock Therapeutics is laying off 50 employees and shuttering its research labs in Cambridge, Massachusetts, in ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader ...

The FDA is shutting the door to imports of certain endoscope hardware manufactured by Olympus, saying that a production site in Japan has failed to meet quality requirements. | The FDA is shutting the ...

Arbutus Biopharma had made no secret of its plans to step up its work on imdusiran. | Arbutus had made no secret of its desire to step up its plans for imdusiran. Now, the company has regained the ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

Brain metastases are common in ROS1-positive NSCLC, particularly after disease progression. Among 56% with measurable brain ...

Only last month, the Massachusetts-based company was outlining plans to lay off half of its employees in order to focus its ...